Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
reports
Ultragenyx Pharmaceutical (RARE) Stock Price & Analysis
347 Followers
RARE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$33.36 - $85.53
Previous Close$43.72
Volume449.66K
Average Volume (3M)761.20K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$888.67M
Total Debt (Recent Filing)$34.68M
Price to Earnings (P/E)-4.5
Beta-0.93
Next EarningsFeb 16, 2023
EPS Estimate-$2.14
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$89.92
EPS (TTM)-9.74
Shares Outstanding70,105,654
R-Squared0.11
Standard Deviation0.16
10 Day Avg. Volume752,646
30 Day Avg. Volume761,196
Price to Book (P/B)10.94
Price to Sales (P/S)11.43
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-6.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside105.67% Upside
Rating ConsensusStrong Buy
Alpha0.00525
Number of Analyst Covering12
Ultragenyx Pharmaceutical News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RARE FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $33.36 and its highest was $85.53 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Currently, no data Available
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is Feb 16, 2023 which is in 17 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on Nov 02, 2022. The company reported -$3.5 earnings per share for the quarter, missing the consensus estimate of -$1.811 by -$1.689.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -$2.14.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 70,105,650 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$3.5 in its last earnings report, missing expectations of -$1.811. Following the earnings report the stock price went down -5.962%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Among the largest hedge funds holding Ultragenyx Pharmaceutical’s share is Echo Street Capital Management LLC. It holds Ultragenyx Pharmaceutical’s shares valued at 650K.
---
Ultragenyx Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.92
$89.92
Blogger Sentiment
Neutral
RARE Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 22.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 35.3%
Last 30 Days ▲ 35.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.03%
12-Months-Change
Fundamentals
Return on Equity
-96.69%
Trailing 12-Months
Asset Growth
9.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
---
Arrowhead Pharmaceuticals
―
Beam Therapeutics
―
PTC Therapeutics
―
Blueprint Medicines
―
IVERIC bio
―
---